Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
Charlie Kirk Mourning: Crowd Gathers Hours Before Event Begins As Thousands Attend At Arizona Stadium - VIDEO
Sahibzada Farhan Celebrates Fifty With Gunshot Celebration During IND Vs PAK Asia Cup 2025 Super 4 Match; Video
Voyage’25 Brings Together Tourism, Technology, And Culture At Jai Hind College
Kanpur News: 20-Year-Old Restaurant Worker Murdered By Colleague, Body Found In Suitcase
